Adams PC, Barton JC, Guo H, Alter D, Speechley M

Idioma: Ingles.
Referencias bibliográficas: 26
Paginas: 348-353
Archivo PDF: 137.92 Kb.

RESUMEN

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Camaschella C, Poggiali E. Towards explaining “unexplained hyperferritinemia”. Haematologica 2009; 94: 307-9.

2. Kannengiesser C, Jouanolle AM, Hetet G, Mosser A, Muzeau F, Henry D, Bardou-Jacquet E, et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 2009; 94: 335-39.

3. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, et al. Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population. N Engl J Med 2005; 352: 1769-78.

4. McLaren CE, Barton JC, Adams PC, Harris E, Acton R, Press N, Reboussin DM, et al. Hemochromatosis and Iron Overload Screening (HEIRS) Study Design for an Evaluation of 100,000 Primary Care-Based Adults. Am J Med Sci 2003; 325: 53-62.

5. Gordeuk VR, Reboussin DM, McLaren CE, Barton JC, Acton RT, McLaren GD, Harris EL, et al. Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population. Am J Hematol 2008; 83: 618-26.

6. Adams PC, Passmore L, Chakrabarti S, Reboussin D, Acton R, Barton J, McLaren GD, et al. Liver diseases in the Hemochromatosis and Iron Overload Screening Study. Clin Gastroenterol Hepatol 2006; 4: 918-23.

7. Pankow JS, Boerwinkle E, Adams PC, Guallar E, Leiendecker- Foster C, Rogowski J, Eckfeldt J. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Translational Research 2008; 152: 3-10.

8. Powell L, Dixon J, Ramm G, Purdie DM, Lincoln D, Anderson G, Subramaniam N, et al. Screening for hemochromatosis in asymptomatic subjects with and without a family history. Arch Int Med 2006; 166: 294-301.

9. Falize L, Guillygomarch A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44: 472-7.

10. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 2011; 162: 949-57.

11. Beaton M, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II Clinical Trial of phlebotomy therapy for non-alcoholic liver disease. Aliment Pharmacol Ther 2013: 37: 720-9.

12. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-8.

13. Houschyar KS, Ludtke R, Dobos GJ, Kalus U, Broecker- Preuss M, Rampp T, Brinkhaus B, et al. Effects of phlebotomy- induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med 2012; 10: 54.

14. Bofill C, Joven J, Bages J, Vilella E, Sans T, Cavalle P, Miralles R, et al. Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus. Metabolism 1994; 43: 614-20.

15. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and betacell function. Diabetes 2002; 51: 1000-04.

16. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and all-cause mortality—the Copenhagen City Heart Study. Eur Heart J 2010; 31: 1624-32.

17. Maiwall R, Kumar S, Chaudhary AK, Maras J, Wani Z, Kumar C, Rastogi A, et al. Serum ferritin predicts early mortality in patients with decompensated cirrhosis. J Hepatol 2014; 61: 43-50.

18. Walker NM, Stuart KA, Ryan RJ, Desai S, Saab S, Nicol JA, Fletcher LM, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010; 51: 1683-91.

19. Al-Freah MA, Kriese S, Foxton MR, Quaglia A, Bomford A, Heaton ND, O’Grady JG, et al. The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome? Transpl Int 2013; 26: 1070-9.

20. Barton JC, Lafreniere SA, Leiendecker-Foster C, Li H, Acton RT, Press RD, Eckfeldt JH. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 353 Ferritin and mortality. , 2015; 14 (3): 348-353 785 HEIRS Study participants. Am J Hematol 2009; 84: 710-4.

21. Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood 1976; 48: 449-55.

22. Barton J, Acton R, Dawkins F, Adams P, Lovato L, Leiendecker- Foster C, McLaren CE, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the hemochromatosis and iron overload screening study. Genet Test 2005; 9: 231-41.

23. Harris EL, McLaren CE, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. Arch Intern Med 2007; 167: 722-6.

24. Ellervik C, Marott JL, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Total and Cause-Specific Mortality by Moderately and Markedly Increased Ferritin Concentrations: General Population Study and Meta-analysis. Clin Chem 2014; 60: 1419-28.

25. Stack A, Mutwali A, Nguyen H, Cronin C, Casserly L, Ferguson J. Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population. QJM 2014; 107: 623-33.

26. Menke A, Muntner P, Fernandez-Real JM, Guallar E. The association of biomarkers of iron status with mortality in US adults. Nutr Metab Cardiovasc Dis 2012; 22: 734-40.